Regulatory GSK eyes October FDA verdict on chronic hep B drug PharmaphorumGSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.Infectious DiseaseRead full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Merck KGaA and Remepy join forces to develop combo drug-digital therapiesNext: Coultreon banks $125M to support testing of former Galapagos immune drug Related Stories Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026 Regulatory GSK claims FDA okay for first oral carbapenem antibiotic pharminent June 18, 2026 Regulatory uniQure sets course to US filing for Huntington gene therapy pharminent June 17, 2026
